drugset / Trial / NCT00306904
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF. The target population are patients with diabetic macular edema.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-09
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bevasiranib | Unknown | 0.2 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 1.5 mg | Intravitreal |
| Subject | bevasiranib | Unknown | 3 mg | Intravitreal |